Colon cancer
Conditions
Interventions
Test drug(Daikenchuto) is taken orally between preoperative day 2 and postoperative twelve week.
No treatment
Sponsors
Nagasaki University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients who qualify for curative colonic resection (solely via laparoscopic surgery) for colon cancer. Preoperative staging of disease: I, II, IIIa, IIIb TNM category distribution: T=1-3, N=0-2, M=0 2)PS (ECOG Performance Status Scale): 0, 1 3)Patients who can orally administration of Daikenchuto 4)Age: over 20 yo. 5)Gender: no specification 6)Inpatient/Outpatient: Inpatient 7)Patients who can provide written informed consent
Exclusion criteria
Exclusion criteria: 1)Patients with a history of laparotomy and endoscopic surgery 2)Patients with concomitant inflammatory bowel disease (ulcerative colitis, Crohn disease) 3)Patients requiring emergency surgery 4)Patients with double cancer 5)Patients with serious liver disorder 6)Patients with serious renal disorder 7)Patients with history of laparotomy and peritonitis (excludes surgery for appendicitis) 8)Patients who are taking other Kampo formulation(s) 9)Patients who are pregnant, possibly pregnant, nursing or considering pregnancy 10)Others, including patients who are unfit for the study as determined by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| GSRS(Japanese Version) score Weight change ratio | — |
Secondary
| Measure | Time frame |
|---|---|
| Albumin Total protein PNI Pre albumin Retinal binding protein - Total cholesterol - CRP | — |
Countries
Japan
Contacts
Public ContactFumihiko Fujita
Nagasaki University Hospital Department of transplantation and digestive surgery
Outcome results
None listed